Cargando…

MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer

BACKGROUND: Metastatic castration resistant prostate cancer (mCRPC) is incurable and progression after drugs that target the androgen receptor-signaling axis is inevitable. Thus, there is an urgent need to develop more effective treatments beyond hormonal manipulation. We sought to identify activate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nickols, Nicholas G., Nazarian, Ramin, Zhao, Shuang G., Tan, Victor, Uzunangelov, Vladislav, Xia, Zheng, Baertsch, Robert, Neeman, Elad, Gao, Allen C., Thomas, George V., Howard, Lauren, De Hoedt, Amanda M., Stuart, Josh, Goldstein, Theodore, Chi, Kim, Gleave, Martin E., Graff, Julie N., Beer, Tomasz M., Drake, Justin M., Evans, Christopher P., Aggarwal, Rahul, Foye, Adam, Feng, Felix Y., Small, Eric J., Aronson, William J., Freedland, Stephen J., Witte, Owen N., Huang, Jiaoti, Alumkal, Joshi J., Reiter, Robert E., Rettig, Matthew B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6853839/ https://www.ncbi.nlm.nih.gov/pubmed/30804427 http://dx.doi.org/10.1038/s41391-019-0134-5

Ejemplares similares

Transcriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticity
por: Westbrook, Thomas C., et al.
Publicado: (2022)

Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance
por: Alumkal, Joshi J., et al.
Publicado: (2020)

Practice patterns and outcomes of equivocal bone scans for patients with castration-resistant prostate cancer: Results from SEARCH
por: Hanyok, Brian T., et al.
Publicado: (2019)

The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer
por: Lundberg, Arian, et al.
Publicado: (2023)

UDP-glucuronosyltransferases and biochemical recurrence in prostate cancer progression
por: Grant, Delores J., et al.
Publicado: (2017)

Validity of the National Death Index to Ascertain the Date and Cause of Death in Men Having Undergone Prostatectomy for Prostate Cancer
por: Moghanaki, Drew, et al.
Publicado: (2019)

Quantitative assessment of PSMA PET response to therapy in castration-sensitive prostate cancer using an automated imaging platform for disease identification and measurement
por: Duriseti, Sai, et al.
Publicado: (2023)

Nutrition, dietary interventions and prostate cancer: the latest evidence
por: Lin, Pao-Hwa, et al.
Publicado: (2015)

Androgen receptor amplification is concordant between circulating tumor cells and biopsies from men undergoing treatment for metastatic castration resistant prostate cancer
por: Podolak, Jennifer, et al.
Publicado: (2017)

Estimated Costs and Long-term Outcomes of Patients With High-Risk Non–Muscle-Invasive Bladder Cancer Treated With Bacillus Calmette-Guérin in the Veterans Affairs Health System
por: Williams, Stephen B., et al.
Publicado: (2021)

Significant changes in macrophage and CD8 T cell densities in primary prostate tumors 2 weeks after SBRT
por: Kane, Nathanael, et al.
Publicado: (2022)

KRAS-MEK Signaling Controls Ago2 Sorting into Exosomes
por: McKenzie, Andrew J., et al.
Publicado: (2016)

Quality-of-life impact of interstitial cystitis and other pelvic pain syndromes
por: Cunningham, Andrew R., et al.
Publicado: (2023)

Accurate cancer phenotype prediction with AKLIMATE, a stacked kernel learner integrating multimodal genomic data and pathway knowledge
por: Uzunangelov, Vladislav, et al.
Publicado: (2021)

A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone
por: Graff, Julie N, et al.
Publicado: (2020)

National prevalence of IC/BPS in women and men utilizing veterans health administration data
por: Anger, Jennifer T., et al.
Publicado: (2022)

Inhibiting MEK in MAPK pathway-activated myeloma
por: Heuck, C J, et al.
Publicado: (2016)

Are higher follicle-stimulating hormone levels before androgen deprivation therapy for prostate cancer associated with oncological and cardiac outcomes and overall survival?—a population-level analysis
por: Dymanus, Kyle, et al.
Publicado: (2023)

MEK genomics in development and disease
por: Bromberg-White, Jennifer L., et al.
Publicado: (2012)

Risk factors for MEK-associated retinopathy in patients with advanced melanoma treated with combination BRAF and MEK inhibitor therapy
por: Booth, Andrew E. C., et al.
Publicado: (2020)

Mek1 and Mek2 Functional Redundancy in Erythropoiesis
por: Beuret, Laurent, et al.
Publicado: (2021)

Keratin 13 Is Enriched in Prostate Tubule-Initiating Cells and May Identify Primary Prostate Tumors that Metastasize to the Bone
por: Liu, Sandy, et al.
Publicado: (2016)

Novel non-AR therapeutic targets in castrate resistant prostate cancer
por: Toren, Paul J., et al.
Publicado: (2013)

5-α reductase inhibitors and prostate cancer prevention: where do we turn now?
por: Hamilton, Robert J, et al.
Publicado: (2011)

Efficacy of MEK Inhibition in Patients with Histiocytic Neoplasms
por: Diamond, Eli L., et al.
Publicado: (2019)

Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer
por: Graff, Julie N., et al.
Publicado: (2016)

Systemic and tumor-directed therapy for oligometastatic prostate cancer: study protocol for a phase II trial for veterans with de novo oligometastatic disease
por: Parikh, Neil R., et al.
Publicado: (2019)

MEK Inhibitor U0126 Reverses Protection of Axons from Wallerian Degeneration Independently of MEK–ERK Signaling
por: Evans, Catherine, et al.
Publicado: (2013)

Predicting bone scan positivity in non-metastatic castration-resistant prostate cancer
por: Moreira, Daniel M., et al.
Publicado: (2015)

A phase 3 randomised study of enzalutamide plus leuprolide and enzalutamide monotherapy in high-risk non-metastatic hormone-sensitive prostate cancer with rising PSA after local therapy: EMBARK study design
por: Freedland, Stephen J, et al.
Publicado: (2021)

Fish Oil Slows Prostate Cancer Xenograft Growth Relative to Other Dietary Fats and is Associated with Decreased Mitochondrial and Insulin Pathway Gene Expression
por: Lloyd, Jessica C., et al.
Publicado: (2013)

Radiation therapy dose and androgen deprivation therapy in localized prostate cancer: a meta-regression of 5-year outcomes in phase III randomized controlled trials
por: Jiang, Tommy, et al.
Publicado: (2021)

Negative regulation of TGF-β1-induced MKK6-p38 and MEK-ERK signalling and epithelial-mesenchymal transition by Rac1b
por: Witte, David, et al.
Publicado: (2017)

El jet's mek' /
por: Romero de Nieto, Carmen
Publicado: (1986)

Obesity and prostate cancer-specific mortality after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database
por: Vidal, A C, et al.
Publicado: (2017)

Increased women’s empowerment and regional inequality in Sub-Saharan Africa between 1995 and 2015
por: Rettig, Erica M., et al.
Publicado: (2022)

The Influence of Hepatic Function on Prostate Cancer Outcomes Following Radical Prostatectomy
por: Bañez, Lionel L., et al.
Publicado: (2010)

Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor
por: Coleman, Daniel J., et al.
Publicado: (2016)

Allocating HIV Prevention Funds in the United States: Recommendations from an Optimization Model
por: Lasry, Arielle, et al.
Publicado: (2012)

Depression as a risk factor for adverse outcomes in coronary heart disease
por: Freedland, Kenneth E, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_sq2utnqbuer6ur8mf1cm3m0j03